Top

Published in:

01-11-2006 | Original Article

A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results

Authors: Andreas A. Argyriou, Elisabeth Chroni, Angelos Koutras, Gregoris Iconomou, Spiridon Papapetropoulos, Panagiotis Polychronopoulos, Haralabos P. Kalofonos

Published in: Supportive Care in Cancer | Issue 11/2006

Abstract

Aim

A randomized, open label with blind assessment, controlled trial was performed to assess efficacy and adverse-event profile of vitamin E, given as supplementation for prophylaxis against cisplatin-induced peripheral neuropathy (CIPN).

Patients and methods

A total of 30 patients scheduled to receive six courses of cumulative cisplatin-based regimens were randomly allocated to treatment and control groups and were then studied by means of neurological examination and electrophysiological study. Patients assigned to group I (n=14) orally received vitamin E at a daily dose of 600 mg/day during chemotherapy and 3 months after its cessation were compared to patients of group II (n=16), who received no vitamin E supplementation and served as controls. The severity of neurotoxicity was summarized by means of a modified Peripheral Neuropathy (PNP) score.

Results

The incidence of neurotoxicity differed significantly between groups, occurring in 3/14 (21.4%) of patients assigned to the vitamin E supplementation group and in 11/16 (68.5%) of controls (p=0.026). The relative risk (RR) of developing neurotoxicity was significantly higher in case of controls, RR=2.51, 95% C.I.=1.16–5.47. Mean PNP scores were 4.99±1.33 for patients of group I and 10.47±10.62 for controls, (p=0.023). None of the adverse events or deaths occurred, were judged as likely to be related to the vitamin E supplementation.

Conclusion

Vitamin E effectively and safely protects patients with cancer from occurrence of cisplatin neurotoxicity.

Alberts DS, Noel JK (1995) Cispaltin-associated neurotoxicity: can it be prevented? Anticancer Drugs 6:369–383CrossRefPubMed

Argyriou AA, Chroni E, Koutras A, Ellul J, Papapetropoulos S, Katsoulas G, Iconomou G, Kalofonos HP (2005) Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial. Neurology 64(1):26–31PubMed

Berger T, Malayeri R, Doppelbauer A, Krajnik G, Huber H, Auff E, Pirker R (1997) Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur J Cancer 33(9):1393–1399CrossRefPubMed

Bove L, Picardo M, Maresca V, Jandolo B, Pace A (2001) A pilot study on the relationship between cisplatin neuropathy and vitamin E. J Exp Clin Cancer Res 20(2):277–280PubMed

Brigelius-Flohe R, Kelly FJ, Salonen JT, Neuzil J, Zingg JM, Azzi A (2002) The European perspective on vitamin E: current knowledge and future research. Am J Clin Nutr 76(4):703–716PubMed

Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR (1994) Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies. Ann Neurol 35:304–311CrossRefPubMed

Dyck PJ, Thomas PK (eds) (1993) Peripheral neuropathy, vol 2, 3 edn. WB Saunders, Philadelphia, PA, pp 1310–1317

Gregg RW, Molepo JM, Monpetit VJ, Mikael NZ, Redmond D, Gadia M, Stewart DJ (1992) Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurological tissue and morphological evidence of toxicity. J Clin Oncol 10:795–803PubMed

Halliwell B, Gutteridge JMC (1993) Free radicals in biology and medicine. Oxford University Press, Oxford, pp 188–276

10.

Hathcock JN, Azzi A, Blumberg J et al (2005) Vitamins E and C are safe across a broad range of intakes. Am J Clin Nutr 81(4):736–745PubMed

11.

Kimura J (2001) Electrodiagnosis in diseases of nerve and muscle, principles and practice, 3rd edn. Oxford University press, pp 91–166

12.

Kleyweg RP, Van der Meché FGA, Schmitz PIM (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain–Barré syndrome. Muscle Nerve 14:1103–1109CrossRefPubMed

13.

Ko HY, Park-Ko I (1999) Electrophysiologic recovery after vitamin E-deficient neuropathy. Arch Phys Med Rehabil 80(8):964–967CrossRefPubMed

14.

Leonetti C, Biroccio A, Gabellini C et al (2003) Alpha-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy. Int J Cancer 104(2):243–250CrossRefPubMed

15.

Manzella D, Barbieri M, Ragno E, Paolisso G (2001) Chronic administration of pharmacologic doses of vitamin E improves the cardiac autonomic nervous system in patients with type 2 diabetes. Am J Clin Nutr 73:1052–1057PubMed

16.

Miller ER 3rd, Pastor-Barriuso R, Dalal D et al (2005) Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142(1):37–46PubMed

17.

Morinobu T, Ban R, Yoshikawa S, Murata T, Tamai H (2002) The safety of high dose vitamin E supplementation in healthy Japanese male adults. J Nutr Sci Vitaminol 48(1):6–9PubMed

18.

Pace A, Savarese A, Picardo M, Maresca V, Pacetti U, Del Monte G, Biroccio A, Leonetti C, Jandolo B, Cognetti F, Bove L (2003) Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol 21(5):927–931CrossRefPubMed

19.

Panayiotopoulos CP, Chroni E (1996) F-waves in clinical neurophysiology: a review. Methodological issues and overall value in peripheral neuropathies. Electroencephalogr Clin Neurophysiol 101:365–374PubMed

20.

Park SA, Choi KS, Bang JH, Huh K, Kim SU (2000) Cisplatin-induced apoptotic cell death in mouse hybrid neurons is blocked by antioxidants through suppression of cisplatin-mediated accumulation of p53 but not of Fas/Fas ligand. J Neurochem 75(3):946–953CrossRefPubMed

21.

Peltier AC, Russell JW (2002) Recent advances in drug-induced neuropathies. Curr Opin Neurol 15(5):633–638CrossRefPubMed

22.

Satya-Murti S, Howard L, Krohel G, Wolf B (1986) The spectrum of neurological disorder from vitamin E deficiency. Neurology 36:917–921PubMed

23.

Traber MG, Sokol RJ, Ringel SP, Neville HE, Thellman CA, Kayden HJ (1987) Lack of a-tocopherol in peripheral nerves of vitamin E patients with peripheral neuropathy. N Engl J Med 317:262–285PubMedCrossRef

24.

Weijl NI, Hopman GD, Wipkink-Bakker A, Lentjes EG, Berger HM, Cleton FJ, Osanto S (1998) Cisplatin combination chemotherapy induces a fall in plasma antioxidants of cancer patients. Ann Oncol 9(12):1331–1337CrossRefPubMed

25.

Windebank AJ (1999) Chemotherapeutic neuropathy. Curr Opin Neurol 12:565–571CrossRefPubMed

Title: A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results
Authors: Andreas A. Argyriou
Elisabeth Chroni
Angelos Koutras
Gregoris Iconomou
Spiridon Papapetropoulos
Panagiotis Polychronopoulos
Haralabos P. Kalofonos
Publication date: 01-11-2006
Publisher: Springer-Verlag
Published in: Supportive Care in Cancer / Issue 11/2006
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-006-0072-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Aim

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2006

Long-term, tunneled, noncuffed central venous catheter in cancer patients (Vygon): safety, efficacy, and complications

Breaking bad news: evaluation study on self-perceived competences and views of medical and nursing students taking part in a collaborative workshop

Supportive care needs of people with brain tumours and their carers

Assessing cognitive function in cancer patients

Society News November issue 2006

The WHO analgesic ladder for cancer pain control, twenty years of use. How much pain relief does one get from using it?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer